Financial

Neovasc Announces First Quarter 2021 Financial Results

VANCOUVER and MINNEAPOLIS, May 06, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today reported financial results for the first quarter ended March 31, 2021. First Quarter Highlights Generated revenue of $451,794 in the quarter as Neovasc Reducer™ implants rebounded after being suppressed for much of 2020 […]

Cytokinetics Reports First Quarter 2021 Financial Results

Secondary Analysis from GALACTIC-HF to be Presented in Late Breaking Clinical Trial Session at ACC.21 Company Plans to Submit NDA for Omecamtiv Mecarbil following Recent Meeting with FDA Results from REDWOOD-HCM Expected Mid-Year; Open Label Extension Study and Phase 3 Clinical Trial Planning Underway SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) […]

Lexicon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical Update

Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 06, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2021 and provided an update on key milestones. “We continue to enroll patients in our two proof-of-concept Phase […]

Caladrius Biosciences Reports First Quarter 2021 Financial Results and Provides Business Update

Conference call begins today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J. , May 06, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial […]

Xenter, Inc. Appoints Industry Leaders Robert S. Langer, Elazer R. Edelman, David J. Bearss and Mark Stautberg to Board of Directors; Closes $12M Series A

-Xenter’s Expanding Team of Industry Leaders Poised to Advance Device/Data/Drug Technologies for Interventional Medicine, Pharmaceutical Advancements and Digital Health- SALT LAKE CITY–(BUSINESS WIRE)–Xenter, Inc. (XenterMD.com), the world’s first start-up Device-Data-Drug healthcare technologies company, today announced the appointment of four additional industry leaders to its Board of Directors and the closing of […]

CARMAT’s Board of Directors is reorganising its governance and proposes the appointment of three new directors to support the new strategic phase of industrialization and commercialization

The Board of Directors warmly thanks Dr. Philippe Pouletty, Managing Director of Truffle Capital, for his exceptional contribution to the development of the CARMAT project, and proposes the appointment of three new directors, Florent Battistella, David Coti and John B. Hernandez. CARMAT (FR0010907956, ALCAR), the designer and developer of the […]